Latham & Watkins Advises atai Life Sciences in Upsized IPO

Capital markets team represents the clinical-stage biopharmaceutical company in the offering.

June 21, 2021

atai Life Sciences B.V., a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, has announced the pricing of its upsized initial public offering in the United States of 15,000,000 common shares at a price to the public of US$15 per share. All common shares are being offered by atai. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by atai, are expected to be US$225 million. In addition, atai has granted the underwriters a 30-day option to purchase up to an additional 2,250,000 common shares at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on June 22, 2021, subject to customary closing conditions. atai’s common shares are expected to begin trading on the Nasdaq Global Market on June 18, 2021 under the ticker symbol “ATAI.”

Latham & Watkins LLP represents atai Life Sciences in the offering with a capital markets team led by New York partners Nathan Ajiashvili and Ian Schuman and Frankfurt partner Oliver Seiler, with associates Jennifer Gascoyne, Victoria McGrath, Ryan Hudson, and Hamna Ahmad.

 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.